Clinical Editors Corner

Jeannie Yu1,2,3, MD, FACC, FSCCT, and Morton J. Kern1,2,3, MD, MSCAI, FAHA, FACC
8/3/2018   |   644 views

How we understand patients with aortic stenosis has changed as the therapeutic approach has evolved.

continue reading
Morton J. Kern, MD, MSCAI, FACC, FAHA
7/8/2018   |   6,380 views

Recently, manual compression has emerged as a potentially viable alternative to shorter radial artery hemostasis times.

continue reading
Morton J. Kern, MD, and Arnold H. Seto, MD, MPA Dr. Seto is the Chief of Cardiology at Long Beach VA Medical Center, in Long Beach, California.  
5/29/2018   |   2,902 views

A question came from one of our cath lab staff, who asked if we could describe how chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is done and what the options are for a successful procedure.

continue reading
Morton J. Kern, compiler, with contributions from Andrew Doorey, Christiana Hospital, Delaware; Kirk Garratt, Christiana Hospital, Delaware; John Hirshfeld, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; David Kandzari, Piedmont Hospital, Atlanta, Georgia; Michael Lim, St. Louis University, St. Louis, Missouri; Jeffery Moses, Columbia University, New York, New York; Pinak Bipin Shah, Brigham and Women’s Hospital, Boston, Massachusetts; Will Suh, University of California, Los Angeles, California; Paul Teirstein, Scripps Clinic, La Jolla, California; Chris White, Ochsner Medical Center, New Orleans, Louisiana; George Vetrovec, Medical College of Virginia, Richmond, Virginia; Jeannie Yu, VA Long Beach, California
5/7/2018   |   1,123 views

Dr. Paul Teirstein, Chief of Cardiology, at Scripps Clinic, La Jolla, California, asked our cath lab experts for their opinions on what to do with an asymptomatic executive who had a screening CTA (Figure 1).

continue reading
Morton J. Kern, MD
4/5/2018   |   3,497 views

In everyone’s career life, including the nursing and technical staff in the cath lab, mentors take on a multitude of roles during the training periods and early work life, and continue to have an impact well into the future years of the daily experiences in the lab.

continue reading
Morton J. Kern, MD, with contributions from Andrew Michaels, MD, Director of the Cardiac Catheterization Laboratory at St. Joseph Hospital in Eureka, California; Jim Blankenship, MD, The Geisinger Clinic, Harrisburg, Pennsylvania; Jeff Moses, MD, Columbia University, New York City, New York; Lloyd Klein, MD, Rush University, Chicago, Illinois; Charles Chambers, MD, Pennsylvania State University, Harrisburg, Pennsylvania.
3/2/2018   |   1,791 views

One of our colleagues, Andrew Michaels, MD, Director of the Cardiac Catheterization Laboratory at St. Joseph Hospital in Eureka, California, recently asked about the consent process for cardiac cath cases. 

continue reading
Morton J. Kern, MD
2/6/2018   |   2,297 views

When FFRCT and angio-derived FFR technology ultimately become more widely available, they will radically change the way diagnostic angiography is performed in the same way that invasive FFR changed the way we approach patients needing PCI. 

  continue reading
Morton Kern, MD Clinical Editor; Chief of Medicine, Long Beach Veterans Administration Health Care System, Long Beach, California; Associate Chief Cardiology, Professor of Medicine, University of California Irvine, Orange, California mortonkern2007@gmail.com
1/2/2018   |   4,007 views

Stimulated by a couple of recent articles on the efficiency of the RADPAD protection drape in reducing operator’s exposure1 and the effects of shielding on nurses and technologists in the cath lab2, I thought it would be a good idea to see what was new and what we should be thinking about to reduce radiation exposure to ourselves, our team, and our patients.  

continue reading
Morton J. Kern, with contributions from Richard Bach, Barnes Jewish Hospital, St. Louis, Missouri; Steven R. Bailey, University of Texas Health Sciences Center at San Antonio, Texas; Charles Chambers, Harrisburg, Pennsylvania; David J. Cohen, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Larry S. Dean, University of Washington, Seattle, Washington; Greg Dehmer, Temple, Texas; Ted Feldman, Evanston, Illinois; Kirk Garratt, Christiana Hospital, Newark, Delaware; Ajay Kirtane, Columbia University, New York City, New York; Lloyd Klein, Chicago, Illinois; Mitchell W. Krucoff, Duke University Medical Center, Raleigh, North Carolina; Jeffrey J. Popma, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Duane Pinto, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Fred Resnic, Lahey Clinic, Burlington, Massachusetts; Gregg Stone, Columbia University, New York City, New York; Zoltan Turi, Hackensack University Medical Center, Hackensack, New Jersey; George Vetrovec, Medical College of Virginia, Richmond, Virginia.   
12/5/2017   |   4,194 views

Many of the editor’s pages come from issues raised by practicing interventionalists. Recently, a query came to our colleague, Dr. Zoltan Turi, from a chief of cardiology.

continue reading
Morton J. Kern, MD, with the collaboration of Drs. Zoltan Turi, Co-Director, Structural and Congenital Heart Center, Hackensack University Medical Center, Hackensack, New Jersey; Chet Rihal, Chair, Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota; Matthew Price, Director Interventional Cardiology, Scripps Clinic, La Jolla, California; Jonathan Tobis, University of California, Los Angeles, California; Jeffery Moses, Professor of Medicine, Columbia University, New York, New York.  
11/5/2017   |   1,306 views

Given the infrequency with which we perform TSP, I asked my expert cath lab colleagues about the need for more heparin in TSP for only diagnostic purposes. In addition, I also asked, “Does the anticoagulation regimen differ for each type of procedure? Do we need to ever worry about too much anticoagulation since the electrophysiology (EP) operators do TSPs even with high INR values?”

continue reading